<DOC>
	<DOCNO>NCT01148459</DOCNO>
	<brief_summary>The purpose study assess safety immunogenicity candidate malaria vaccine HIV-infected infant child</brief_summary>
	<brief_title>Safety Immunogenicity GSK Biologicals ' Investigational Malaria Vaccine HIV Infected Infants Children</brief_title>
	<detailed_description>This protocol post update due protocol Amendment 2 .</detailed_description>
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Vaccines</mesh_term>
	<mesh_term>Lactitol</mesh_term>
	<criteria>All subject must satisfy ALL follow criterion study entry : A male female infant child include 6 week 17 month age , time first vaccination . Signed thumbprinted informed consent obtain parent ( ) /LAR ( ) infant child . Where parents/LARs illiterate , consent form countersign witness . Subjects investigator believe parents/LARs comply requirement protocol enrol study . Subjects know HIVinfected ( document positive DNA PCR ) , whether take HIV antiretroviral treatment ( ART ) . Subjects born follow normal gestation period . The following criterion check time study entry . If ANY exclusion criterion applies , subject must include study : Acute disease time enrolment . However , presence illness list Grade I Grade II ( WHO pediatric AIDS clinical staging ) constitute exclusion criterion . Enrolment defer axillary temperature &gt; =37.5°C . Grade III Grade IV abnormality screen laboratory blood sample . Grade III IV AIDS time enrolment ( WHO pediatric AIDS clinical staging ) . Major congenital defect . Planned administration/administration vaccine foreseen study protocol prior within 7 day study vaccine . Use investigational nonregistered product ( drug vaccine ) study vaccine 30 day precede Dose°1 study vaccine , plan use study period . Previous participation malaria vaccine trial . Simultaneous participation another clinical trial include administration experimental treatment . Same sex twin . History allergic reaction ( significant IgEmediated event ) anaphylaxis previous immunization . History allergic disease reaction likely exacerbate component study vaccine . Child care .</criteria>
	<gender>All</gender>
	<minimum_age>6 Weeks</minimum_age>
	<maximum_age>17 Months</maximum_age>
	<verification_date>April 2017</verification_date>
	<keyword>Plasmodium falciparum</keyword>
	<keyword>schedule</keyword>
	<keyword>HIV</keyword>
	<keyword>malaria vaccine</keyword>
	<keyword>EPI</keyword>
	<keyword>Africa</keyword>
</DOC>